Naltrexone for Antipsychotic-Induced Weight Gain (NTX)

Conditions

Bipolar Depression | Schizoaffective Disorder | Schizophrenia | Schizophreniform Disorder | Severe Major Depression With Psychotic Features

What is the purpose of this trial?

This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications. Naltrexone is an FDA approved medication for the management of alcohol dependence and drug dependence, but has not been fully evaluated for its effect on weight loss in individuals with severe mental illness (i.e. schizophrenia, schizoaffective disorder, bipolar disorder etc.) The purpose of this study is to find out how effective two different doses of oral naltrexone is on reducing body weight when compared to placebo (an inactive substance or "sugar pill").


Participation Guidelines

Age:
18 Years - 75 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Institute of Mental Health
Dates:
10/18/2012
Last Updated:
Study HIC#:
1207010507